7762.Two

The company maintains a strong capital structure, with a debt-to-equity ratio of 0.09, indicating a low reliance on debt financing. However, its liquidity position is assessed as medium, with a current ratio of 10.68, suggesting the company has sufficient short-term assets to cover its liabilities. Despite this, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 2.13%, and its return on assets (ROA) is 1.85%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company may not be generating returns as efficiently as its peers. The operating margin, calculated as operating income divided by revenue, is 6.63%, which is a key metric for assessing operational efficiency in the industry.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risks if market conditions in its primary market deteriorate. The absence of detailed segment and geographic data limits the ability to assess the company's exposure to different markets and product lines.

The company's growth trajectory appears to be modest, with no significant revenue growth reported in the latest financial data. The capital expenditure of -29,877,000 TWD suggests that the company is not investing heavily in new projects or infrastructure, which could impact its long-term growth potential. The free cash flow of 24,473,000 TWD indicates that the company has some flexibility to fund operations or return value to shareholders, but the lack of substantial investment may hinder future expansion.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting that the company may need to secure additional financing in the near term. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted figures, indicating that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's latest actual earnings per share (EPS) of 0.46 TWD and revenue of 222,032,000 TWD suggest stable performance, but there is no indication of significant new developments or strategic shifts in the near term.